Idiopathic hypersomnia: management

Evidence-based neurology checklist on idiopathic hypersomnia: management: HLA studies It is not associated with HLA DR2 or DQB1 Multiple sleep latency test (MSLT) Polysomnography Cerebrospinal fluid (CSF) Treatments Investigational treatments

HLA studies

  • It is not associated with HLA DR2 or DQB1

Multiple sleep latency test (MSLT)

Polysomnography

Cerebrospinal fluid (CSF)

Treatments

Investigational treatments

References

  1. Bassetti C, Aldrich MS. Idiopathic hypersomnia: a series of 42 patients. Brain 1997; 120:1423-1435.
  2. Anderson KN, Pilsworth S, Sharples LD, Smith IE, Shneerson JM. Idiopathic hypersomnia: a study of 77 cases. Sleep 2007; 30:1274-1281.
  3. Morse AM, Naik S. Idiopathic hypersomnia: neurobiology, diagnosis, and management. CNS Drugs 2023; 37:305-322.
  4. Lavault S, Dauvilliers Y, Drouot X, et al. Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Med 2011; 12:550-556.
  5. Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol 2022; 21:53-65.
  6. And 5 more. Subscribe to see the full list

Related checklists

Loading...